Small Molecule Activators of Antitumor Immunity

Area of Science:

• Chemical biology
• Cancer immunotherapy
• Immunology

Background:

• Immune checkpoint blockade therapies show promise but are limited by dysfunctional T-cells in the tumor microenvironment.
• Aged hosts exhibit impaired immune fitness and reduced responsiveness to PD-1/PD-L1 therapies due to metabolic and signaling deficits.
• Chemical modulation of immune cell function offers a strategy to overcome these limitations.

Purpose of the Study:

• To explore the use of small molecules to restore T-cell activity and enhance antitumor immunity.
• To identify chemical mechanisms that can synergize with immune checkpoint blockade.
• To develop strategies to overcome age-associated immune dysfunction in cancer therapy.

Main Methods:

• Cell-based screening and electrophile-focused chemoproteomics to identify small-molecule modulators.
• Profiling of spermidine-interacting proteins using chemoproteomic tools.
• In vivo assessment of identified small molecules for restoring mitochondrial fitness and enhancing antitumor immunity.

Main Results:

• Identification of arvenin I, a covalent activator of MKK3, which revives exhausted T-cells and synergizes with immune checkpoint blockade.
• Discovery that age-associated spermidine depletion impairs T-cell metabolism and checkpoint blockade response.
• Identification of a biostable spermidine mimetic that restores mitochondrial function and enhances in vivo antitumor immunity.

Conclusions:

• A chemical biology framework combining covalent signaling activation and metabolite-inspired energy support can restore T-cell fitness.
• Chemoproteomic discovery can guide the development of novel immune-activating small molecules.
• Chemical approaches hold significant potential to complement and extend the efficacy of cancer immunotherapy, particularly in aged individuals.